Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of autologous hemotopoietic stem cell (HSC) gene therapy, AVR-RD-02, compared to enzyme replacement therapy, for the treatment of Gaucher disease Type 3 in male and female participants aged 2 to 25 years. The study will consist of 2 parts - Core (Part 1) followed by the ERT-crossover (Part 2)


Clinical Trial Description

Core (Part 1) Once a participant consents, he/she will complete the screening period within 30 days. Eligible participants will have baseline assessments completed 30 days later and then will be randomized into one of two treatment arms: AVR-RD-02 arm or ERT control arm. If randomized to the AVR-RD-02 arm, the participant will enter the pre-gene therapy infusion period (approximately 15 weeks), which consists of mobilization, apheresis, AVR-RD-02 preparation and testing for release, discontinuation of ERT, and conditioning. The participant will then receive the AVR-RD-02 gene therapy (1 day) followed by a 52-week follow-up period in which periodic safety and efficacy assessments will be performed. Participants will not receive ERT after gene therapy infusion unless indicated by pre-specified laboratory and clinical criteria. If randomized to the ERT Control arm, the participant will remain on their prescribed ERT regimen for 52-week observation period with approximately 4 study visits during this time. ERT-crossover (Part 2) After 52 weeks of observation in Part 1, participants in the ERT Control Arm will have the opportunity to enter Part 2 and receive AVR-RD-02. They will start with baseline assessments and follow a similar schedule to the schedule followed by participants assigned to AVR-RD-02 in the Core Study (Part 1). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05815004
Study type Interventional
Source AVROBIO
Contact
Status Withdrawn
Phase Phase 2/Phase 3
Start date October 2023
Completion date December 2027

See also
  Status Clinical Trial Phase
Completed NCT01685216 - Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease Phase 1/Phase 2
Completed NCT04002830 - A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease Phase 4
Terminated NCT03746587 - Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 Phase 2
Recruiting NCT05447494 - Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease Phase 1/Phase 2
Recruiting NCT04532047 - In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases Phase 1
Recruiting NCT05586243 - MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)